{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:10:19Z","timestamp":1790669419563,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008250","name":"Feinberg School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008250","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.prp.2022.154299","type":"journal-article","created":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T01:58:13Z","timestamp":1672451893000},"page":"154299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The role of PRAME and NY-ESO-1 as potential therapeutic and prognostic biomarkers in triple-negative breast carcinomas"],"prefix":"10.1016","volume":"241","author":[{"given":"Sharlene Helene C.","family":"See","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Finkelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carissa","family":"LaBoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi P.","family":"Siziopikou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Luis Z.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2022.154299_bib1","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results Program (SEER). Cancer Stat Facts: Female Breast Cancer. \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html\u3009. (Accessed 28 November 2021)."},{"key":"10.1016\/j.prp.2022.154299_bib2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.tranon.2018.01.011","article-title":"A comprehensive immunologic portrait of triple-negative breast cancer","volume":"11","author":"Liu","year":"2018","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.prp.2022.154299_bib3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1158\/2326-6066.CIR-13-0088","article-title":"Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers","volume":"2","author":"Yao","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.prp.2022.154299_bib4","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/sj.bjc.6604494","article-title":"PRAME expression and clinical outcome of breast cancer","volume":"99","author":"Epping","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2022.154299_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-007-9643-3","article-title":"Prevalence and prognostic and predictive relevance of PRAME in breast cancer","volume":"109","author":"Doolan","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.prp.2022.154299_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-018-1757-3","article-title":"PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer","volume":"17","author":"Al-Khadairi","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.prp.2022.154299_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.breast.2019.12.002","article-title":"Expression of tumor-associated antigens in breast cancer subtypes","volume":"49","author":"Curigliano","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.prp.2022.154299_bib8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.breast.2018.08.106","article-title":"Expression of NY-ESO-1, MAGE-A3, PRAME and WT-1 in different subgroups of breast cancer: an indication to immunotherapy?","volume":"42","author":"Tessari","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.prp.2022.154299_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2020.107231","article-title":"Immunopeptidome screening to design an immunogenic construct against PRAME positive breast cancer: an in silico study","volume":"85","author":"Afzali","year":"2020","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.prp.2022.154299_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.15171\/bi.2019.06","article-title":"In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens","volume":"9","author":"Parvizpour","year":"2019","journal-title":"BioImpacts"},{"key":"10.1016\/j.prp.2022.154299_bib11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41379-018-0153-0","article-title":"Breast cancer global tumor biomarkers: a quality assurance study of intratumoral heterogeneity","volume":"32","author":"Clark","year":"2019","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2022.154299_bib12","unstructured":"Residual Cancer Burden Calculator and Associated Documents (Guide for Measuring Cancer Cellularity, Examples of Gross and Microscopic Evaluation, Pathology Protocol for Macroscopic and Microscopic Assessment of RCB), MD Anderson Cancer Center, Houston, Texas. \u3008http:\/\/www.mdanderson.org\/breast\u3009 cancer_RCB. (Accessed 19 July 2021)."},{"key":"10.1016\/j.prp.2022.154299_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7754\/Clin.Lab.2013.121137","article-title":"PRAME gene expression in childhood acute lymphoblastic leukemia","volume":"60","author":"Abdelmalak","year":"2014","journal-title":"Clin. Lab."},{"key":"10.1016\/j.prp.2022.154299_bib14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.gene.2016.09.016","article-title":"PRAME is critical in breast cancer growth and metastasis","volume":"594","author":"Sun","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.prp.2022.154299_bib15","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2022.154299_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13569-017-0077-3","article-title":"Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes","volume":"7","author":"Roszik","year":"2017","journal-title":"Clin. Sarcoma Res."},{"key":"10.1016\/j.prp.2022.154299_bib17","doi-asserted-by":"crossref","first-page":"10376","DOI":"10.1111\/jcmm.16967","article-title":"Cancer testis antigen PRAME: an anti-cancer target with immunomodulatory potential","volume":"25","author":"Naik","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.prp.2022.154299_bib18","doi-asserted-by":"crossref","first-page":"7372","DOI":"10.1093\/nar\/gkm896","article-title":"Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors","volume":"35","author":"Renaud","year":"2007","journal-title":"Nucleic Acids Res."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S034403382200543X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S034403382200543X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:59:07Z","timestamp":1759733947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S034403382200543X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":18,"alternative-id":["S034403382200543X"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2022.154299","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of PRAME and NY-ESO-1 as potential therapeutic and prognostic biomarkers in triple-negative breast carcinomas","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2022.154299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154299"}}